MIRA reports preclinical data: topical Ketamir-2 comparable to injected morphine in pain model

MIRA PHARMACEUTICALS, INC.

Topical Ketamir-2 nearly eliminated paw licking and markedly reduced paw lifting in both acute (0-10 min) and inflammatory (15-60 min) phases.
Comparable efficacy to injected morphine across both pain phases; effects consistent across all 5-min intervals.
Company continues Phase 1 oral Ketamir-2 trial; Phase 2a in neuropathic pain expected later in 2025.
Topical Ketamir-2 is being developed as potential non-opioid treatment for diabetic neuropathy, osteoarthritis, and other pain conditions.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.